131 results
8-K
EX-99.1
FOLD
Amicus Therapeutics Inc
5 Dec 23
Amicus Therapeutics Congratulates Executive Chairman John F. Crowley on Appointment as Next President and CEO of BIO
6:03am
’ Lead Independent Director, said, “On behalf of the Board of Directors and the company, we thank John for his outstanding leadership and commitment
8-K
EX-10.1
rxjpvewi2m p79zkwjai
2 Oct 23
Entry into a Material Definitive Agreement
8:48am
8-K
EX-99.1
wx33g54k
2 Oct 23
Entry into a Material Definitive Agreement
8:48am
8-K
EX-99.1
8bryy66m
28 Sep 23
Amicus Therapeutics Announces FDA Approval and Launch of New Treatment for Pompe Disease
12:00pm
8-K
EX-99.1
hcy9s8srarzl3aceouj9
15 Aug 23
Amicus Therapeutics Announces Approval and Launch of New Pompe Disease Therapy in the United Kingdom
7:00am
8-K
EX-99.1
2ho q04obakjh1
27 Jun 23
Amicus Therapeutics Announces Approval and Launch of New Pompe Disease Therapy in the European Union
7:01am
8-K
EX-10.1
bsf1u537
12 May 23
Entry into a Material Definitive Agreement
5:08pm
8-K
EX-99.2
pq1wv0 ltnirguqzy3
10 May 23
Amicus Therapeutics Announces First Quarter 2023 Financial Results and Corporate Updates
7:01am
8-K
EX-99.1
vhq2fd2dfqdzd3xhd
26 Apr 23
Amicus Therapeutics Receives Positive CHMP Opinion for Opfolda® (miglustat) for Late-Onset Pompe Disease
2:04pm
8-K
EX-99.1
poq7b1zvhd2c if
16 Nov 22
Corporate OverviewNovember 2022At the Forefront of Therapies for Rare Diseases
7:01am
8-K
EX-99.2
ngl1 clij17ihxq
7 Nov 22
Amicus Therapeutics Provides EU Regulatory Update for AT-GAA
2:31pm